Erratum: Assessment of fractionated exhaled nitric oxide as a biomarker for the treatment of eosinophilic esophagitis
نویسندگان
چکیده
ciency. Diagnosis and HLA studies in a French-Canadian family. J Clin Invest 60:1061–1069, 1977. 24. Zeitz HJ, Miller GW, Lint TF, et al. Deficiency of C7 with systemic lupus erythematosus: Solubilization of immune complexes in complement-deficient sera. Arthritis Rheum 24:87–93, 1981. 25. Alcalay M, Bontoux D, Peltier A, et al. C7 deficiency, abnormal platelet aggregation, and rheumatoid arthritis. Arthritis Rheum 24:102–103, 1981. 26. Kojima K, Sasaki A, Yokomatsu Y, et al. Deficiency of the seventh component of complement with systemic lupus erythematosus. Osaka City Med J 31:121–128, 1985. 27. Segurado OG, Arnaiz-Villena AA, Iglesias-Casarrubios P, et al. Combined total deficiency of C7 and C4B with systemic lupus erythematosus (SLE). Clin Exp Immunol 87:410 – 414, 1992. 28. Amano T, Miyashima H, Mitsuhashi Y, et al. Deficiency of the 9th component of complement associated with rheumatoid arthritis. Jpn J Clin Immunol 4:206–211, 1981. 29. Sugimoto M, Nishikai M, Sato A, et al. SLE-like and sicca symptoms in late component (C9) complement deficiency. Ann Rheum Dis 46:153–155, 1987. 30. Kawai T, Katoh K, Narita M, et al. Deficiency of the 9th component of complement (C9) in a patient with systemic lupus erythematosus. J Rheumatol 16:542–543, 1989. 31. Takeda I, Igarashi S, Nishimaki T, and Kasukawa R. A case of systemic lupus erythematosus in late component (C9) complement deficiency. Ryumachi 34:628–632, 1994. 32. Ichikawa E, Furuta J, Kawachi Y, et al. Hereditary complement (C9) deficiency associated with dermatomyositis. Br J Dermatol 144:1080–1083, 2001. 33. Inai S, Akagaki Y, Moriyama T, et al. Inherited deficiencies of the late-acting complement components other than C9 found among healthy blood donors. Int Arch Allergy Appl Immunol 90:274–279, 1989. 34. Fukumori Y, Yoshimura K, Ohnoki S, et al. A high incidence of C9 deficiency among healthy blood donors in Osaka, Japan. Int Immunol 1:85–89, 1989. 35. Zhu Z, Atkinson TP, Hovanky KT, et al. High prevalence of complement component C6 deficiency among African-Americans in the south-eastern USA. Clin Exp Immunol 119:305–310, 2000. 36. Orren A, Owen EP, Henderson HE, et al. Complete deficiency of the sixth complement component (C6Q0), susceptibility to Neisseria meningitidis infections and analysis of the frequencies of C6Q0 gene defects in South Africans. Clin Exp Immunol 167:459–471, 2012.. e
منابع مشابه
Assessment of fractionated exhaled nitric oxide as a biomarker for the treatment of eosinophilic esophagitis
Diagnosis of eosinophilic esophagitis (EoE) and determination of response to therapy is based on histological assessment of the esophagus, which requires upper endoscopy. In children, in whom a dietary approach is commonly used, multiple endoscopies are needed, because foods are eliminated and then gradually reintroduced. Ideally, noninvasive methods could supplement or replace upper endoscopy ...
متن کاملNon- and semi-invasive methods of monitoring eosinophilic esophagitis.
BACKGROUND/AIMS Monitoring inflammation associated with eosinophilic esophagitis (EoE) relies on the identification of biomarkers that provide an objective measure of disease activity. To date, this metric has been the number of eosinophils in the squamous epithelial tissue. The search for alternative biomarkers as well as alternative methods to capture them has been the topic of much research....
متن کاملDrug-induced eosinophilic pneumonia in a patient with Crohn's disease: diagnosis and treatment using fraction of exhaled nitric oxide
Oral 5-aminosalicylic acid agents (mesalazine and sulfasalazine) and azathioprine are the mainstays of treatment for inflammatory bowel disease. Reports of pulmonary toxicity induced by oral 5-aminosalicylic acid agents or azathioprine in patients with inflammatory bowel disease are very rare; to date, only 38 cases have been reported worldwide. We, herein, report a case involving a 26-year-old...
متن کاملExhaled nitric oxide measurements: clinical application and interpretation.
The use of exhaled nitric oxide measurements (F(E)NO) in clinical practice is now coming of age. There are a number of theoretical and practical factors which have brought this about. Firstly, F(E)NO is a good surrogate marker for eosinophilic airway inflammation. High F(E)NO levels may be used to distinguish eosinophilic from non-eosinophilic pathologies. This information complements conventio...
متن کاملAre known biomarkers for asthma present in early infancy?
Background Exhaled nitric oxide (FENO) is a biomarker for eosinophilic airway inflammation [1]. Elevated FENO has been proposed as a marker for diagnosing asthma and predicting asthma exacerbations [2]. We wished to examine the association between known asthma risk factors and FENO. A sub cohort of children (n=222) participating in the Canadian Healthy Infant Longitudinal Development (CHILD) st...
متن کاملExhaled nitric oxide levels in patients with atopic cough and cough variant asthma.
BACKGROUND AND OBJECTIVE Atopic cough (AC) is an established clinical entity in Japan, in which patients present with a chronic persistent non-productive cough. Exhaled nitric oxide (NO) is a biomarker of eosinophilic airway inflammation. The present study examined whether exhaled NO levels were increased in AC in comparison with cough variant asthma (CVA) and bronchial asthma (BA). METHODS C...
متن کامل